Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis

por Yavin, Yshai, Mansfield, Traci A., Ptaszynska, Agata, Johnsson, Kristina, Parikh, Shamik, Johnsson, Eva
Publicado 2016

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies

por Fioretto, Paola, Mansfield, Traci A., Ptaszynska, Agata, Yavin, Yshai, Johnsson, Eva, Parikh, Shamik
Publicado 2016

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

por Bailey, Clifford J, Gross, Jorge L, Hennicken, Delphine, Iqbal, Nayyar, Mansfield, Traci A, List, James F
Publicado 2013

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

por Bailey, Clifford J, Gross, Jorge L, Hennicken, Delphine, Iqbal, Nayyar, Mansfield, Traci A, List, James F
Publicado 2013